deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT01161498

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck

Sponsor: Amgen

Conditions Head and Neck Cancer Squamous Cell Carcinoma
Interventions Cisplatin Radiation Talimogene Laherparepvec
Updated 6 times since 2017 Last updated: Jan 14, 2016 Started: Feb 28, 2011 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).

Other terminated trials from Amgen

See all terminations from Amgen

Other Head and Neck Cancer trials with similar outcome

Browse all Head and Neck Cancer trials

This PHASE3 trial investigates Head and Neck Cancer and Squamous Cell Carcinoma and is currently terminated or withdrawn. Amgen leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • BioVex Limited
Data source: BioVex Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations